Atoltivimab
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA) -approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection[1].
Product Specifications
CAS Number
2135632-29-8
Product Name Alternative
REGN3470
UNSPSC
12352203
Target
Filovirus
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/atoltivimab.html
Purity
98.66
Solubility
10 mM in DMSO
Smiles
[Atoltivimab]
Molecular Weight
(145.1 kDa)
References & Citations
[1]Saxena D, et al. Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus. Drugs Today (Barc) . 2021 Aug;57 (8) :483-490.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
EBOV
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K2160507 1.0 µg DNA
SLC6A3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)
Sign In for Pricing
View Details